Daily Stock List
Far East Energy Corp. (FEEC)
SmarTrend Newsletters and AllPennyStocks reported recently on Far East Energy Corp. (FEEC), PennyTrader Publisher did earlier, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Houston, Texas, Far East Energy Corp. engages in the acquisition, exploration, development, and production of coalbed methane gas properties in the People's Republic of China. The Company holds, via production sharing contracts, interests in three of China's largest coalbed methane fields. These are the 485,000-acre Shouyang Block in Shanxi Province; the 573,000-acre Qinnan Block in Shanxi Province; and the 265,000-acre Enhong and Laochang areas in Yunnan Province. The Company has offices in Beijing, Kunming, and Taiyuan City, China.
Far East Energy is the operator under a Product Sharing Contract (PSC) entered into with China United Coalbed Methane Company, Ltd. (CUCBM) to develop the Shouyang Block in the Shanxi Province. The term of the Shouyang PSC consists of an exploration period, a development period, and a production period. During the exploration period, Far East Energy holds a 100 percent participating interest in the properties, and the Company must bear all exploration costs for discovering and evaluating CBM-bearing areas.
Far East Energy is the operator under a PSC with China National Petroleum Company (CNPC), the successor to CUCBM, to develop the Qinnan Block in the Shanxi Province. On January 25, 2002, Far East Energy entered into a PSC with CUCBM to develop two areas in the Yunnan Province. These are the Enhong area, which covers approximately 145,198 acres and the Laochang area, which covers approximately 119,772 acres. Far East Energy is the operator under the PSC.
In July 2011, Far East Energy announced the results of an independent engineering report prepared by Netherland, Sewell & Associates, Inc. (NSAI) updating estimates for the total coalbed methane Original Gas-in-Place (OGIP) in Far East Energy's Shouyang Block situated in Shanxi Province, China. This follows the July 22, 2011 release of NSAI's updated report covering net contingent gas resources and net contingent cash flows from the Shouyang Block project. Both reports reflected large increases.
On January 9, 2012, Far East Energy announced the signing of a Modification Agreement extending the exploration period of their Production Sharing Contract in Yunnan Province. The Modification Agreement signed by Far East Energy (Bermuda), Ltd. (Far East Energy) and China United Coal Bed Methane (CUCBM) will now forward to the Ministry of Commerce (MofCom) of the People's Republic of China for formal approval.
Far East Energy Corp. (FEEC) closed on Friday at $0.33, up 0.92%, on 396,061 volume with 54 trades. The average volume for the last 60 days is 1,601,803. The 52-week low/high is $0.11/$0.69.
La Jolla Pharmaceutical (LJPC)
OTCPicks and Greenbackers reported earlier on La Jolla Pharmaceutical (LJPC) and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
La Jolla Pharmaceutical is a biopharmaceutical company with corporate headquarters in San Diego, California. The Company's dedication is to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. La Jolla Pharmaceutical established in 1989. The Company's shares trade on the OTCQB.
GCS-100 is the Company's product candidate. GCS-100 is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure. Encouraging work conducted by investigators at the Ludwig Cancer Institute has shown that galectin-3 inhibits the activity of cancer-killing T-cells. It has also shown that pharmacologically blocking galectin-3 with GCS-100 reactivates these T-cells. Furthermore, several independent, academic studies have concluded that galectin-3 is a mediator of fibrosis (scar formation) after heart, kidney, lung, and liver injury.
GCS-100's ongoing development as an anti-cancer and anti-fibrotic agent has as its support extensive preclinical and clinical investigation. This includes Phase 1 and Phase 2 clinical trials involving over 140 patients. Experimental results to date indicate that GCS-100 specifically inhibits galectin-3 in immune cells isolated from patients, and confers anti-cancer activity in patients with several tumor types. It also exhibits effects on the immune system in patients consistent with its galectin-3 inhibitory mechanism, and is safe and well tolerated at doses that confer clinical activity.
Today, La Jolla Pharmaceutical announced that they acquired worldwide development and commercialization rights to GCS-100 from privately held Solana Therapeutics, Inc. Galectin-3 plays a key role in the immune system's response to cancer and tissue injury. This makes specific inhibitors of galectin-3 attractive therapeutic candidates for a broad spectrum of life-threatening diseases. This includes cancer, heart failure, kidney disease, pulmonary fibrosis, and liver fibrosis.
In connection with the acquisition, Mr. George F. Tidmarsh, M.D., Ph.D., received appointment as the Company's President and Chief Executive Officer. Dr. Tidmarsh's 22 years of experience in biotechnology include the successful clinical development of three FDA-approved drugs. Up until his appointment to La Jolla, Dr. Tidmarsh served as the Chief Executive Officer of Solana Therapeutics, Inc. He previously served as the Chief Executive Officer of Horizon Pharma, Inc., a company he founded in 2005.
La Jolla Pharmaceutical (LJPC) closed on Friday at $0.0056, up 60.00%, on 21,844,335 volume with 249 trades. The average volume for the last 60 days is 385,914. The 52-week low/high is $0.002/$4.10.
Callisto Pharmaceuticals, Inc. (CLSP)
OTC Picks, HotOTC, BullRally, Stock Rich, and CoolPennyStocks reported previously on Callisto Pharmaceuticals, Inc. (CLSP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Incorporated in May 2003, Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. They focus primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through two subsidiary companies. These are Synergy Pharmaceuticals Inc. and Callisto Research Labs, LLC. In addition, they own two inactive subsidiaries, IgX, Ltd. (Ireland) and Callisto Pharma, GmbH (Germany). Callisto Pharmaceuticals has their corporate headquarters in New York, New York. The Company's shares trade on the OTC Bulletin Board.
The Company's lead drug candidates are Plecanatide and SP-333. Plecanatide is a guanylyl cyclase C (GC-C) receptor agonist. It is to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C). SP-333 is a second-generation GC-C receptor agonist. It is currently in pre-clinical development to treat gastrointestinal inflammatory diseases.
Callisto Pharmaceuticals' drug candidates also include Atiprimod. This drug is in Phase II clinical trial for low-to-intermediate grade neuroendocrine cancers, primarily in advanced carcinoid cancer patients. Atiprimod is an orally available small molecule drug that displays a multiplicity of anti-cancer mechanistic activities. Atiprimod has also completed single and multiple dose phase I clinical trials for the treatment of rheumatoid arthritis.
In addition, the Company's drug candidates include L-Annamycin. This is an anthracycline drug for leukemia therapy. L-Annamycin is a liposome nanoparticle formulation of annamycin, a second generation anthracycline. It has undergone development to address shortcomings with the current generation anthracycline drugs to treat relapsed acute leukemia patients. L-Annamycin has the potential to work against anthracycline-resistant tumors. The expectation is that it will have reduced cardiotoxicity. Callisto has a license agreement with the University of Texas M.D. Anderson Cancer Center to research, develop, sell, and commercialize the patent rights for L-Annamycin.
Callisto Pharmaceuticals has one preclinical development program, Degrasyns. Callisto licensed Degrasyns from the M. D. Anderson Cancer Center in January of 2005. The Company maintains a collaborative development program on this class of novel anti-cancer compounds.
Callisto Pharmaceuticals, Inc. (CLSP) closed on Friday at $0.26, even with yesterdays’ close, on 6,500 volume with 2 trades. The average volume for the last 60 days is 53,311. The 52-week low/high is $0.22/$0.83.
IC Places, Inc. (ICPA)
Bull in Advantage and Pennybuster reported this week on IC Places, Inc. (ICPA), Greenbackers did recently, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
IC Places is a Multi Media Entertainment Company that produces "Made for TV" and "New Media" video programs. At the core of the Company is a network of 350 city-based entertainment websites. Each IC Places City website offers a virtual keyhole view of life in each community. Every unique aspect of a city's social, business, and cultural life is available at each city's IC Places homepage. IC Places has their production offices in Hollywood, California.
From 2005 to 2011, the Company focused their efforts on building the IC Places website. In August of 2011, IC Places signed respected Hollywood insiders Charlotte Parker and Joel Parker to their Board of Advisors. The Parkers consult in the development of content and programming.
In September of 2011, IC Places formed a production and marketing partnership with Hi Point Studios. Hi Point Studios is in Los Angeles, California. Under the partnership, IC Places has exclusive access to the television shows and movies undergoing filming at Hi Point Studios. The Company then delivers to their viewers, behind the scenes, "1st Look" shows featuring the actors, directors, as well as producers of these films and television shows. The partnership gives IC Places additional content for their websites, and it gives them the studio space they require to begin creating long form TV shows.
IC Places long-term goal is to become a New Media Entertainment company that will create personality-driven entertainment for online, television, and film. In November 2011, the Company started production on their first TV show in Hollywood. The show, Static, was created with partner FunnyBrand777, a company headed by Brandon Gibson a veteran filmmaker, actor, and comedian. IC Places shot four episodes in December 2011. They are currently editing them for TV. They are in talks with a comedy-based television network to become the home of the show.
On December 20, 2011, IC Places signed their first television programming agreement with Brighthouse Networks. The agreement is for their new TV show "IC Places Hollywood." Under the agreement, the show will air in six cities and IC Places receives half of the commercial revenues. IC Places Hollywood will be available on demand.
IC Places, Inc. (ICPA) closed on Friday at $0.001, down 9.09%, on 59,204,381 volume with 100 trades. The average volume for the last 60 days is 14,842,239. The 52-week low/high is $0.0009/$0.29.
Optex Systems Holdings, Inc. (OPXS)
Nebula Stocks, Stock traders chat, PennyOmega.com, and DrStockPick.com reported earlier on Optex Systems Holdings, Inc. (OPXS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Optex Systems Holdings, Inc. is a leading manufacturer of optical sighting systems and assemblies. These are primarily for Department of Defense applications. Optex also manufactures and delivers a number of periscope configurations, rifle and surveillance sights, as well as night vision optical assemblies. Founded in 1987, Optex Systems Holdings has their headquarters in Richardson, Texas.
The Company delivers their products both directly to the military services and to prime contractors. Their products undergo installation on different types of U.S. military land vehicles. These include the Abrams and Bradley fighting vehicles, Light Armored and Armored Security Vehicles. They have been selected for installation on the Stryker family of vehicles.
Optex serves customers in three primary categories. These are as prime contractor (TACOM, U.S. Army, Navy and Marine Corps), as subcontractor (General Dynamics, BAE, Raytheon and Northrop) and as a supplier to foreign governments (Israel, Australia and NAMSA). The Company delivers high volume products, under multi-year contracts, to large defense contractors. They also anticipate the opportunity to integrate some of their night vision and optical sights products into retail applications.
Specific product lines include electronic sighting systems, mechanical sighting systems, laser protected glass periscopes, and laser protected plastic periscopes. Product lines also include non-laser protected plastic periscopes, Howitzer sighting systems, ship binoculars, and replacement optics (e.g. filters and mirrors).
Earlier this month, Optex Systems Holdings announced operating results for their fiscal year ended October 2, 2011. Revenues for the year ending October 2, 2011 were $16.2 million, compared to revenues for the year ending October 3, 2010 of $22.9 million. This represents a decrease of $6.7 million or 29 percent. The reduction in revenues was primarily attributable to decreased spending by the U.S government.
During the year, ending October 2, 2011, net income was $0.6 million compared to a net loss of $10 million for the year ended October 3, 2010. The Company's EBITDA increased by $0.84 million for the year ending October 2, 2011, compared to the year ending October 3, 2010, despite the significant decrease in revenues.
Optex Systems Holdings, Inc.
) closed on Friday at $0.02, up 77.78%, on 1,013,666 volume with 29 trades. The average volume for the last 60 days is 82,832. The 52-week low/high is $0.001/$0.02.
Kiwibox.com Inc. (KIWB)
InsideBulls reported recently on Kiwibox.com Inc. (KIWB), HotStockChat, Stockpalooza did previously, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Headquartered in New York, New York, Kiwibox.com Inc. is a social community network. Kiwibox owns and operates Kiwibox.com, a leading destination site that has more than 10 years experience as a social network. Kiwibox has combined "magazine" content and social networking technology. The Company lists on the OTC Bulletin Board.
Kiwibox.com launched in 1999 to give teenagers a voice on the internet. It was a leader in the teen oriented world for a number of years. In August 2007, Magnitude Information Systems, Inc., an SEC reporting company, bought Kiwibox. In 2008, Kiwibox launched their new 2.0 version and in October 2009, the Company launched their 3.0 version. This expanded their market audience to include young adults.
As of December 31, 2009, Kiwibox Media Inc. merged with Magnitude Information Systems, changing their name to Kiwibox.com, Inc. In the beginning of 2011, Kiwibox acquired pixunity.de a photoblog community and launched their U.S.-Version in the summer of 2011. Since their acquisition in September 2011, "Kwick!" a top 10 social network community based in Germany, is now part of the Kiwibox.com group.
Earlier this month, Kiwibox.com announced the release of the Company's most recent iPhone and Android cell phone APPs update available to both their Kiwibox.com and Kwick.de social network members. In addition to the inclusion of high quality photos, interactivity now allows the Company's users to blog, view, and link updates to comments in the newsfeed in real time, and search for new friends at the touch of their screens. Updating to this version will allow their users to be more easily discovered by friends. It will also allow them to be more interactive within the Kiwibox.com and Kwick.de worldwide communities.
Kiwibox previously announced the success of their mobile kwick APP that was voted the top social network APP for the android operating system, with an approximate market share of more than 50 percent. With both APP updates, Kiwibox and Kwick now cover almost 70 percent of the global cell phone market.
Kiwibox.com Inc. (KIWB) closed on Friday at $0.04, up 0.29%, on 470,800 volume with 12 trades. The average volume for the last 60 days is 701,160. The 52-week low/high is $0.01/$0.06.
PacificHealth Laboratories Inc. (PHLI)
Stock Guru reported previously on PacificHealth Laboratories Inc. (PHLI), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Matawan, New Jersey, PacificHealth Laboratories Inc. is a leading nutrition company. They focus on the development, marketing, and selling of patented premium nutrition tools that enable their consumers to enhance their health and improve their performance. PacificHealth Laboratories is a company driven by science. Two prominent scientists founded the Company.
PacificHealth started with a unique mission to develop innovative nutritional products based on cutting-edge research. The Company developed a working collaboration with some of the world's top nutritionists, biochemists, and sports scientists. Athletes at all levels incorporate PacificHealth's discoveries and products into their daily training and race regimens.
PacificHealth Laboratories' principal area of focus is exercise performance and recovery, including optimal weight management. The Company's products can be marketed without prior Food and Drug Administration (FDA) approval under current regulatory guidelines. The Company's research into factors influencing exercise performance, muscle endurance, and recovery has led to the development and commercialization of a new generation of sports and recovery drinks.
The key to their technology is the specific ratio in which protein is combined with carbohydrates. PacificHealth has received two patents on this technology and more than 18 studies have published demonstrating that products based on this technology can extend endurance, reduce muscle damage, improve rehydration, and accelerate muscle recovery.
PacificHealth offers Endurox R4, a recovery drink; Accelerade, a sports drink; Accel Gel, an advanced sports gel; and 2nd Surge, an ultra energy gel. 2nd Surge is an energy gel that is the first all-natural product specifically formulated to delay the onset of both muscle and brain fatigue.
In addition, they offer Accel Recover, a muscle recovery bar; Endurox Excel, a natural workout supplement; and Accelerade Hydro, a sports drink. PacificHealth Laboratories' sells their products through retail outlets, sports specialty stores, independent health food retailers, independent bike retailers, health clubs, catalogs, Internet sites, and independent distributors.
PacificHealth Laboratories Inc. (PHLI) closed on Friday at $0.20, down 2.44%, on 16,100 volume with 6 trades. The average volume for the last 60 days is 15,447. The 52-week low/high is $0.12/$0.45.
Q Lotus Holdings, Inc. (QLTS)
HotShotStocks, Bull Warrior Stocks, and Buzz Stocks reported previously on Q Lotus Holdings, Inc. (QLTS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Q Lotus Holdings, Inc. is a diversified financial services holding company that lists on the OTC Bulletin Board. The Company provides financing and acquires growing companies in which their management participation in operations can create additional value. The Company was originally incorporated as Extreme Home Staging, Inc. On July 16, 2010, Extreme Home Staging, Inc. underwent a name change to Q Lotus Holdings, Inc. Q Lotus has their corporate headquarters in Chicago, Illinois.
Q Lotus Holdings' principal investment focus is to provide equity and debt capital to growing and middle-market companies with increasing cash flow and escalating income in the following areas: Finance, Real Estate, and Mining. They may invest in other industries if they are presented with attractive opportunities.
The Company's plan is to operate as a multi-industry holding company. Their focus is to acquire and/or develop profitable companies either by obtaining a majority of stock in each company they gain control of or by providing capital investments to companies that internally develop into profitable enterprises. Q Lotus has adopted a business strategy that focuses on expansion via acquisition.
In November 2011, Q Lotus Holdings announced that they are in discussions to hire a senior manager to oversee their mining claims and initiate a mining operations group. The Company has been in discussions with qualified individuals to manage the Q Lotus mining assets to maximize their benefits for the Company, as well as establish a mining operations group for Q Lotus.
Last month, Q Lotus announced that a wholly owned subsidiary of the Company announced plans to initiate and expand the Q Lotus Financial Group. Midwest Business Credit, Inc. (MBCi), a wholly owned subsidiary of Q Lotus Holdings will acquire the assets of Midwest Business Credit LLC (MBC); an asset based lending company that provides secured financing to companies, which are typically deprived of working capital from traditional financial institutions.
Q Lotus Holdings, Inc. (QLTS) closed on Friday at $0.09, up 12.50%, on 39,700 volume with 4 trades. The average volume for the last 60 days is 24,887. The 52-week low/high is $0.03/$1.92.
FrogAds, Inc. (FROG)
The QualityStocks Daily Newsletter would like to spotlight FrogAds, Inc. (FROG). Today, FrogAds, Inc. closed trading at $0.3650, off by 6.41%, on 948,180 volume with 253 trades. The stock’s average daily volume over the past 60-day daily average volume is 182,206 with a 52-week low/high of $0.21/$0.59.
FrogAds, Inc. (FROG) is a rapidly growing company focused on providing a simple yet revolutionary platform for online buying, selling and advertising. Through FrogAds.com, the company enables Internet users to list products and services at no charge in an easy and efficient manner by category and geographical area. The Web site also features online auctioning, photo/movie upload, banner exchange, affordable commercial advertising and more.
From 2000 to 2010, Internet advertising revenues grew from $8.1 billion to over $26.0 billion. This tremendous growth has been attributed to the expanding number of Internet users, which has led to greater advertising success as well as increased acceptance of digital media among the business community. The Internet advertising market continues to grow rapidly with the global industry projected to nearly double by 2014.
FrogAds.com's superior categorization of products and services allows potential buyers to quickly find the product or service specific to their needs. With targeted categorization and a superior platform, FrogAds provides commercial advertisers the ability to target their ads with far greater accuracy than with existing Internet media. Once an ad banner is created, advertisers can chose specific categories, geographical areas and timeframes within a matter of minutes.
FrogAds has carefully evaluated the successes and failures of large websites to remove flaws and become a major contender within the global internet market. FrogAds.com benefits from a highly scalable business model and provides a unique advertising platform to commercial advertisers for accurate targeting strategies. With a rapidly expanding user base and significant market opportunity, the company is well positioned to achieve substantial growth. Disclaimer
FrogAds, Inc. Company Blog
FrogAds, Inc. News:
FrogAds Inc. Opens East Coast Office to Support Expanding Leadership Position in U.S. Internet Advertising Market
FrogAds.com Keeps On Jumping Over the Competition with Increased Visitors and Time Per Visit
FrogAds, Inc. Announces a Major Consumer Advisory Firm Recommends Investments in Company to Expand its Distinctive Classifieds Portal, FrogAds.com
Beacon Enterprise Solutions Group, Inc. (BEAC)
The QualityStocks Daily Newsletter would like to spotlight Beacon Enterprise Solutions Group, Inc. (BEAC). Today, Beacon Enterprise Solutions Group, Inc. closed trading at $0.30 Up, up 10.70%, on 711,660 volume with 39 trades. The stock’s average daily volume over the past 60-days is 39,034 with a 52-week low/high of $0.14/$0.70.
Beacon Enterprise Solutions Group, Inc. (BEAC) specializes in designing, implementing and managing high performance Information Technology Systems ("ITS") infrastructure solutions. Offering national, multi-national and global, turnkey ITS infrastructure solutions, the company is capable of delivery professional services to Fortune 1000 and large multi-site firms as they increasingly single source and outsource to reduce costs while optimizing critical planning, design, program, project and construction management and managed services.
Leveraging standardization, rapid mobilization and a just-in-time professional services approach, Beacon Enterprise Solutions serves as a single source for national, multi-national and global enterprise clients, including special practices focused on data centers, campuses, smart buildings, outside plant, wireless systems and other technology-based applications and projects. Clients are provided with consistent and predictable results anywhere in the world. The company's solutions allow clients to focus on their core businesses without the distraction of having employees spend valuable time on services that Beacon can provide on any continent, in any country using any language.
Headquartered in Louisville, Kentucky, with regional headquarters in Cincinnati, Ohio, Dublin, Ireland, and Prague, Czech Republic, in addition to personnel located throughout the United States and Europe, Beacon Enterprise Solutions services a diverse range of clients. For more than 30 years, the company has enabled businesses in a variety of vertical markets to dramatically reduce costs, enable global standardization, manage day-to-day technology systems moves, adds and changes, and take on major projects – all under a single national, multi-national or global agreement.
Beacon Enterprise Solutions has carefully assembled a seasoned management team and operating strategy to maximize organic growth and new business development across multiple vertical markets. More than 4,000 companies, from small businesses to Fortune 50 firms, have chosen the company's solutions. Disclaimer
Beacon Enterprise Solutions Group, Inc. Blog
Beacon Enterprise Solutions Group, Inc. News:
Beacon Enterprise Solutions Provides Earnings Call Webcast for Fiscal 2011 Financial Results
Beacon Enterprise Solutions Reports Fiscal 2011 Financial Results
Beacon Reports Significant Increases in Service Ticket Volume and Locations Served
FluoroPharma Medical, Inc. (FPMI)
The QualityStocks Daily Newsletter would like to spotlight FluoroPharma Medical, Inc. (FPMI). Today, FluoroPharma Medical, Inc. closed trading at $0.8310, down 4.48%, on 34,940 volume with 5 trades. The stock’s average daily volume over the past 60-day daily average volume is 17,680 with a 52-week low/high of $0.56/$2.15.
FluoroPharma Medical, Inc. (FPMI) is a cutting edge provider of information, content distribution, media management and secure communications to the hospitality industry. The company's state of the art digital technology platform and Internet Protocol (IP) infrastructure presents hotels with a valuable opportunity to generate new revenue while enhancing guests' experiences by providing content that is more relevant to their unique interests.
The company's integrated platform stands far beyond the competition, offering unparalleled guest services such as messaging, folio review, express check outs, energy management and other personalized services while providing the traditional services of Free to Guest (FTG) programming, Video-On-Demand programming, a highly secured high speed internet service and many other interactive services such as gaming.
By combining TV and the web world through unparalleled IPTV/HDTV service, hotels are able to generate additional income through commercial spots, advertisements of local tourist services, hotel promotions and more. Features of the platform includes remote administration, support for more than twenty languages, easy installation and a comprehensive hotel services menu capable of providing detailed information about the hotel and upcoming activities, billing information, room service, guest messages and wake-up services.
The system's architecture consists of a Network Operating Center (NOC) and local hotel servers connected through a point-to-point broadband network. As each guest accesses the network, the resulting traffic generated undergoes analysis based on various criteria. This includes behavioral, geographical, seasonality, and more. Using this data, hotels are able to ensure advertisers maximum value for their advertising budget. Disclaimer
FluoroPharma Medical, Inc. Company Blog
FluoroPharma Medical, Inc. News:
FluoroPharma to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
FluoroPharma Announces Addition to the Board of Directors Reflecting Strong Focus on the Future
FluoroPharma Announces Aggregate of $7M Capital Raise in 2011
Newport Digital Technologies, Inc. (NPDT)
The QualityStocks Daily Newsletter would like to spotlight Newport Digital Technologies, Inc. (NPDT). Today, Newport Digital closed at $0.0002, even for the day, on 2,500 volume with 1 trade. The stock's 60-day daily average volume is 1,759,752 and its 52-week low/high is $0.0002/$0.0056.
Newport Digital Technologies, Inc. (NPDT) offers a rich portfolio of competencies in LED lighting and digital signage. Utilizing its technological expertise and creativity, the company enables its customers to take full advantage of the nearly limitless possibilities offered by increasingly sophisticated applications.
Newport Digital is targeting the sports, entertainment, retail, education, government and hospitality markets. Leveraging partnerships with established electrical contracting and installation partners in the U.S., the company is able to develop and install virtually any digital signage or LED lighting solution, including out-of-home digital signage networks that deliver a powerful in-store advertising platform to retail brands seeking greater return on advertising budgets.
The company has also established partnerships with Taiwan's premier technology incubators, III and ITRI, under which the company develops and customizes their advanced technologies to meet the needs of businesses across the globe. Having a pool of more than 7,900 engineers and scientists, these R&D powerhouses have developed cutting edge capabilities in fields such as Information Communications Technology (ICT), electronics, and nanotechnology.
Newport Digital's management team has accumulated a wealth of knowledge and experience within the technology industry as well as the corporate world. Maintaining a strong track record of delivering exceptional results, the team retains almost two centuries of combined experience. Leveraging each team member's area of expertise, Newport Digital has established a solid foundation to penetrate emerging technology markets. Disclaimer
Newport Digital Technologies, Inc. Blog
Newport Digital Technologies, Inc. News:
Newport Digital Technologies Announces Shareholder Conference Call to Provide Update on Recent Business Developments and Restructuring Plans
Newport Digital Technologies Announces Restructuring Plan
Newport Digital Technologies Partners With Convergent Holdings to Advise on PetCo Park and Retail In-Store Digital Signage Networks
It’s almost impossible to overstate the significance of medical imaging in the development of modern medicine. The New England Journal of Medicine, considered the world’s oldest and single most influential general medical periodical, calls medical imaging one of the top medical developments of the last millennium. You might say that imaging is to medicine what the telescope is to astronomy. Modern medicine would simply not exist without it.
Basically, medical imaging gives health professionals views of the human body, inside and out, to reveal exactly what’s working and what’s not in ways previously not possible. In so doing, it has guided doctors in the saving of countless lives, and has created a multi-billion dollar global industry. It’s an industry that continues to grow, as even small providers realize that they can now purchase used equipment, such as an MRI machine, and realize a hefty return on their investment in a relatively short time, turning a few hundred thousand dollars into millions. Today, the sheer volume of medical imaging has come under fire as feeding the rising costs of health care, a claim hotly contested by the industry.
From its beginnings in 1895, with the discovery of the X-ray, medical imaging has branched out to encompass a range of technologies for uncovering the structure and processes within the human body. Each technology has its own strengths and weaknesses, and is used for identifying specific types of internal problems. Below is a breakdown of the principal imaging technologies used today and what they offer, along with examples of successful publicly traded companies directly associated with them.
• X-Ray – The grandfather of medical imaging, X-rays are still the most frequently used imaging technology. X-ray imaging, a form of highly penetrative electromagnetic radiation, is used for viewing broken bones, but also for dense tumors, as in breast cancer, for lung evaluation, and for spotting foreign objects, such as bullets or swallowed items. Of course it’s also used in dentistry, as well as for non-medical applications, such as security checks at airports.
The best known player in X-rays, and the biggest player in all medical imaging, is General Electric (NYSE: GE), but the company is facing controversy for their earlier announcement of a planned move of its X-ray operations from Wisconsin to China. Varian Medical Systems (NYSE: VAR), based in California, offers hundreds of medical and industrial X-ray tubes, and has a consistent record of growing sales and earnings.
• Computed Tomography (CT) – Usually called CAT scan, CT uses computer processing to combine multiple X-ray images, creating image cross-section slices of a 3D form. It involves more radiation than a standard X-ray, but is good for imaging tumors and various body organs, including the colon, as well as blockages of lung arteries, and for evaluating such things as possible appendicitis. CT scanning has also proven to be an important tool in the war against lung cancer.
Toshiba (OTN: TOSBF), a major producer of imaging and other equipment, is the maker of the award winning Aquilion ONE CT Scanner.
• Magnetic Resonance Imaging (MRI) – MRI uses a strong magnetic field to align various atoms in the body, and then manipulates them with radio waves to generate magnetic signals that can be detected and processed, creating an image. MRI is especially useful for imaging soft tissues, such as breast, heart, and liver, where it is sensitive enough to differentiate diseased tissue from healthy tissue, as well as for fractures, tumors, and arthritis.
Netherlands based Royal Philips Electronics (NYSE: PHG) is a world leader in healthcare related technologies and equipment, producing a wide range of MRI systems.
• Ultrasound – Considered the least invasive in terms of radiation, ultrasound (sometimes called ultrasonography) uses high-frequency sound waves to generate pictures of soft tissues, including real-time moving images, often related to pregnancy or various organs, such as the heart and blood vessels.
Samsung Electronics (OTN: SSNLF), aiming to expand its healthcare market competition with Philips and GE, recently entered the ultrasound market by purchasing a majority stake in South Korean ultrasound manufacturer Medison.
• Positron Emission Tomography (PET) – Unique in its ability to get down to cellular processes, PET, a cutting-edge, rapidly growing branch of nuclear medicine, uses short-lived radioactive chemicals that can, depending upon the chemicals used, provide vital information regarding neurological diseases, heart disease, and cancer. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified.
FluoroPharma Medical (OTCBB: FPMI) does not focus on PET equipment, but rather the critically important imaging agents, the chemicals that allow PET technology to see the cellular processes associated with heart disease and other major diseases. Clinical trials have already confirmed FluoroPharma’s imaging agents are safe and are now establishing their efficacy.
The company’s broad technology platform was developed by scientists at the Massachusetts General Hospital and Harvard Medical School. FluoroPharma has four issued U.S. patents, with seven pending applications, together with strong international protection. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.
La Jolla Pharmaceutical Company, a biopharmaceutical company developing treatments to improve the outcome of patients with life-threatening diseases, today announced that it has acquired global development and commercialization rights to GCS-100, a novel therapeutic for cancer and chronic organ failure.
GCS-100’s ongoing development as an anti-cancer and anti-fibrotic agent is supported by extensive preclinical and clinical investigation, including phase 1 and phase 2 clinical trials.
La Jolla acquired GCS-100 from privately held Solana Therapeutics Inc. (Solana). In connection with the acquisition, former Solana CEO George F. Tidmarsh, M.D., Ph.D. will serve as La Jolla’s new president and CEO.
“Having been involved in the clinical development of GCS-100 over the past several years, I am thrilled to have the opportunity to continue this compound’s development in the context of La Jolla,” Dr. Tidmarsh stated in the press release. “Targeting galectin-3 holds great promise in the treatment of a broad range of life-threatening conditions, and, with GCS-100, we have the most advanced galectin-3-targeting compound in development.”
Dr. Tidmarsh has 22 years of experience in the biotechnology industry, including the successful clinical development of three FDA-approved drugs. In addition to his appointment and also in connection to the acquisition, Saiid Zarrabian was appointed as an independent director of the company. Former members of La Jolla’s management team, including Deirdre Y. Gillespie, M.D., president and CEO, and Gail A. Sloan, CPA, CPA, as well as several former board members, have resigned.
For more information visit www.ljpc.com
INVO Bioscience Inc., a medical device company focused on treatment options for patients diagnosed with infertility, today announced that the National Health Surveillance Agency (ANVISA) in Brazil has granted approval of the INVOcell for use as a Class II device, which will allow the sale of INVOcell in the Brazilian market.
The approval marks a significant milestone in INVO’s history, and opens the door for INVO to tap into one of the largest markets and fastest growing economies in the world.
“Approval in Brazil is a very important step in the success of INVOcell due to the strength of support in the country by medical thought leaders such as Dr. Coelho,” Kathleen Karloff, CEO of INVO stated in the press release. “Today’s announcement paves the way for the more than 125 fertility centers in Brazil to begin offering infertile couples a safe and cost effective solution compared to traditional IVF. We look forward to working with EcoMed, our distribution partner in Brazil, as they begin ramping up their sales and marketing efforts.”
The approval by ANVISA was triggered by the completion of a 40-patient clinical trial conducted in Rio de Janeiro, Brazil, to establish safety, efficacy and comparative in-vitro fertilization (IVF) measures of the INVOcell device.
The trial results, paired with clinical trial results from the Colombian Fertility and Sterility Center (CECOLFES) in Colombia, were submitted to ANVISA for the purpose of gaining registration and approval for the sale of the INVOcell device in Brazil.
INVOcell is CE Mark approved in Europe and Canada and is also available in many South American countries. Karloff noted that if INVOcell can capture 5 percent of the marketplace in Brazil, it could equate to more than $10 million in product sales.
The company also listed several advantages of the INVOcell device, including a reduced occurrence of multiple pregnancies and subsequent costs and complications; relative cost advantages of the INVOcell procedure as compared to traditional IVF treatments; and pregnancy rates comparable to traditional IVF treatments.
For more information visit www.invobioscience.com
US Gold Corp. is a gold and silver exploration company with an emphasis on the Americas. The company is advancing its El Gallo silver and gold project in Mexico, and its Gold bar gold project in Nevada. It has a strong treasury with about $100 million cash along with gold and silver bullion.
Both US Gold and Minera Andes announced today that at each of their respective shareholders meetings on January 19, 2012, stockholders voted in favor of the proposed merger of the two companies. Minera Andes is an explorer of gold, silver and copper in Argentina.
Under the previously announced terms of the deal, Minera Andes’ shareholders will receive 0.45 share of the new company for each share they hold. The newly merged company will change its name to McEwen Mining Inc. The company is being named after the founder, CEO and largest shareholder (20%) of US Gold, Robert McEwen.
His goal has been to grow the company both organically and through acquisitions to become large enough for inclusion in the S&P 500 stock index. After approval of the deal, Mr. McEwen said, “This brings us one step closer to qualifying for the S&P 500. We look forward to future growth and prosperity this combination creates.”
For additional information about the two mining companies, please visit both www.usgold.com and www.minandes.com
Today's Top 3
The QualityStocks Public Company Sponsor News